Biomarkers: Mining the Biofluid Proteome

Veenstra, Timothy D.; Conrads, Thomas P.; Hood, Brian L.; Avellino, Anthony M.; Ellenbogen, Richard G.; Morrison, Richard S.

doi:10.1074/mcp.m500006-mcp200

Cited by 228 publications

(155 citation statements)

References 47 publications

Supporting

Mentioning

149

Contrasting

Unclassified

Order By: Relevance

“…Various non-2-DE based approaches have been successfully developed to study the proteome of biological samples, and a number of new potential plasma/serum biological markers have been described [55]. Proteomics is now established in the medical community and most university hospitals develop such an approach to ameliorate patient care.…”

Section: Clinical Applications -Biomarker Identificationmentioning

confidence: 99%

Recent advances in blood‐related proteomics

et al. 2005

View full text Add to dashboard Cite

Service régional vaudois de transfusion sanguine, Lausanne, SwitzerlandBlood is divided in two compartments, namely, plasma and cells. The latter contain red blood cells, leukocytes, and platelets. From a descriptive medical discipline, hematology has evolved towards a pioneering discipline where molecular biology has permitted the development of prognostic and diagnostic indicators for disease. The recent advance in MS and protein separation now allows similar progress in the analysis of proteins. Proteomics offers great promise for the study of proteins in plasma/serum, indeed a number of proteomics databases for plasma/ serum have been established. This is a very complex body fluid containing lipids, carbohydrates, amino acids, vitamins, nucleic acids, hormones, and proteins. About 1500 different proteins have recently been identified, and a number of potential new markers of diseases have been characterized. Here, examples of the enormous promise of plasma/serum proteomic analysis for diagnostic/prognostic markers and information on disease mechanism are given. Within the blood are also a large number of different blood cell types that potentially hold similar information. Proteomics of red blood cells, until now, has not improved our knowledge of these cells, in contrast to the major progresses achieved while studying platelets and leukocytes. In the future, proteomics will change several aspects of hematology.

show abstract

Section: Clinical Applications -Biomarker Identificationmentioning

confidence: 99%

Recent advances in blood‐related proteomics

et al. 2005

View full text Add to dashboard Cite

show abstract

“…54,55,59 One aspect of patient-centeredness is customized care. 72 Advances in biomarker detection, 73 targeted pharmacogenetics, 74 and tailored communication 75 are making it possible to focus care individually on the specific needs of each patient. eHealth applications will be part of this effort as they assist in providing the right information, to the right person, at the right time.…”

Section: Safetymentioning

confidence: 99%

eHealth Research from the User’s Perspective

Hesse¹,

Shneiderman²

2007

American Journal of Preventive Medicine

126

View full text Add to dashboard Cite

Abstract:The application of information technology (IT) to issues of healthcare delivery has had a long and tortuous history in the United States. Within the field of eHealth, vanguard applications of advanced computing techniques, such as applications in artificial intelligence or expert systems, have languished in spite of a track record of scholarly publication and decisional accuracy. The problem is one of purpose, of asking the right questions for the science to solve. Historically, many computer science pioneers have been tempted to ask "what can the computer do?" New advances in eHealth are prompting developers to ask "what can people do?" How can eHealth take part in national goals for healthcare reform to empower relationships between healthcare professionals and patients, healthcare teams and families, and hospitals and communities to improve health equitably throughout the population? To do this, eHealth researchers must combine best evidence from the user sciences (human factors engineering, human-computer interaction, psychology, and usability) with best evidence in medicine to create transformational improvements in the quality of care that medicine offers. These improvements should follow recommendations from the Institute of Medicine to create a healthcare system that is (1) safe, (2) effective (evidence based), (3) patient centered, and (4) timely. Relying on the eHealth researcher's intuitive grasp of systems issues, improvements should be made with considerations of users and beneficiaries at the individual (patient-physician), group (family-staff), community, and broad environmental levels.(Am J Prev Med 2007;32(5S):S97-S103)

show abstract

“…In the context of biomarker discovery, biological fluids such as plasma or urine, represent the most logical compartment for investigation. Plasma is the best clinical sample in terms of diagnosis and prognosis, due to several advantages including its low cost, not invasive and easy access (Veenstra TD et al, 2005). H u m a n p l a s m a i s a r i c h s o u r c e o f p r o t e i ns and other metabolites which reflect the physiological or clinical status of patients.…”

Section: As Plasma Proteomementioning

confidence: 99%